Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 3.83% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 3.83% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 4 hours ago |
| Up 5% | about 6 hours ago |
| Up 1 ATR | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| Up 3% | about 7 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/31/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid IBD 50 Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid IBD 50 Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 45.23 |
| 52 Week Low | 23.14 |
| Average Volume | 544,050 |
| 200-Day Moving Average | 31.06 |
| 50-Day Moving Average | 40.72 |
| 20-Day Moving Average | 41.47 |
| 10-Day Moving Average | 40.60 |
| Average True Range | 1.76 |
| RSI (14) | 44.13 |
| ADX | 17.49 |
| +DI | 13.22 |
| -DI | 27.53 |
| Chandelier Exit (Long, 3 ATRs) | 39.95 |
| Chandelier Exit (Short, 3 ATRs) | 42.14 |
| Upper Bollinger Bands | 44.30 |
| Lower Bollinger Band | 38.64 |
| Percent B (%b) | 0.13 |
| BandWidth | 13.66 |
| MACD Line | -0.24 |
| MACD Signal Line | 0.24 |
| MACD Histogram | -0.4802 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.14 | ||||
| Resistance 3 (R3) | 42.10 | 41.14 | 41.68 | ||
| Resistance 2 (R2) | 41.14 | 40.43 | 41.16 | 41.52 | |
| Resistance 1 (R1) | 40.24 | 39.99 | 40.69 | 40.28 | 41.36 |
| Pivot Point | 39.28 | 39.28 | 39.50 | 39.30 | 39.28 |
| Support 1 (S1) | 38.38 | 38.57 | 38.83 | 38.42 | 37.34 |
| Support 2 (S2) | 37.42 | 38.13 | 37.44 | 37.18 | |
| Support 3 (S3) | 36.52 | 37.42 | 37.03 | ||
| Support 4 (S4) | 36.56 |
